Phio pharmaceuticals corp. (PHIO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities:
Net loss

-8,908

-7,360

-12,452

-8,994

-10,223

-8,800

-20,925

-12,880

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

67

81

70

53

77

87

99

147

Gain on disposal of property and equipment

-

-

-

-

-

10

-

8

Non-cash lease expense

109

0

-

-

-

-

-

0

Accretion and receipt of bond discount

-

-

-

-

-

-

-

0

Non-cash stock-based compensation expense

300

282

314

756

1,535

1,846

1,979

968

Fair value of common stock warrants issued in exchange for services

-

-

-

-

-

-

-

13

Acquired in-process research and development

-

-

4,696

-

228

-

12,250

-

Deferred taxes

-

-

-1,621

-

-

-

-

-

Value of non-marketable equity securities recognized as revenue

-

-

9

-

-

-

-

-

Value of non-marketable equity securities recognized as revenue

-

-

-

9

-

-

-

-

Fair value of common stock issued in exchange for patent and technology rights

-

-

-

-

-

-

-

6,173

Loss on exchange of Parent Company derivatives

-

-

-

-

-

-

-

0

Fair value of Parent Company's shares mandatorily redeemable for cash upon exercise of warrants

-

-

-

-

-

-

-

0

Fair value of Parent Company's common stock and common stock warrants issued in exchange for services

-

-

-

-

-

-

-

0

Change in fair value of derivatives of Parent Company issued in connection with various equity financings

-

-

-

-

-

-

-

0

Fair value of Parent Company common stock issued in exchange for licensing rights

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Prepaid expenses and other assets

113

2

51

-161

-131

139

89

26

Accounts payable

259

39

-608

-246

878

122

-253

29

Due to former parent

-

-

-

-

-

-

-

597

Accrued expenses and other liabilities

-257

-560

129

519

104

-793

1,028

223

Lease Liability

-102

0

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-47

-71

-400

-298

Net cash used in operating activities

-

-

-

-7,760

-7,317

-7,758

-6,311

-

Net cash used in operating activities

-8,645

-7,520

-9,514

-

-

-

-

-5,062

Cash flows from investing activities:
Change in restricted cash

-

-

-

-

-

-

-3

0

Purchase of short-term investments

-

-

-

2,000

8,000

5,000

9,000

0

Maturities of short-term investments

-

-

-

7,500

2,500

8,000

6,000

0

Cash acquired in MirImmune Inc. acquisition

-

-

100

-

-

-

-

-

Issuance of notes receivable

-

-

-

150

-

-

-

-

Cash paid for purchase of property and equipment

72

5

203

4

57

95

78

15

Proceeds from disposal of property and equipment

-

-

-

-

-

12

-

33

Cash paid for lease deposit

-

-

-

-

-

-

18

2

Net cash provided by investing activities

-

-

-

5,346

-5,557

2,917

-3,093

-

Net cash used in investing activities

-72

-5

-103

-

-

-

-

16

Cash flows from financing activities:
Cash contributions from Parent Company, net

-

-

-

-

-

-

-

699

Proceeds from issuance of Series A convertible preferred stock

-

-

-

-

-

-

-

8,500

Proceeds from issuance of convertible notes payable

-

-

-

-

-

-

-

500

Net proceeds from the issuance of common stock

-

-

290

-

-

1,886

15,651

0

Net proceeds from the issuance of common stock and warrants

708

18,715

0

10,203

9,266

-

-

-

Payment of taxes for net share settled restricted stock unit issuances

3

0

-

-

-

-

-

-

Proceeds from the issuance of common stock upon exercise of pre-funded warrants

72

105

0

-

198

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

5

0

Proceeds from the issuance of common stock in connection with the employee stock purchase plan

1

3

2

-

31

61

28

0

Payments for capital lease obligations less than one year

6

0

-

-

-

-

-

-

Net cash provided by financing activities

772

18,823

292

-

-

-

-

9,670

Net (decrease) increase in cash and restricted cash

-7,945

11,298

-

-

-

-

-

-

Cash paid in lieu of fractional shares for 1:30 reverse stock split

-

-

-

-

-

-

12

0

Repayments of capital lease obligations

-

-

-

-

-

-

5

29

Net cash provided by financing activities

-

-

-

10,203

9,495

1,947

15,667

-

Net decrease in cash and restricted cash

-

-

-9,325

7,789

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-3,379

-2,894

6,263

4,624

Cash received during the period for interest

-

-

-

-

-

-

-

0

Cash paid during the period for interest

-

-

0

-

-

-

-

30

Supplemental disclosure of non-cash investing and financing activities:
Series A and Series A-1 convertible preferred stock dividends

-

-

-

-

-

596

-

-

Fair value of Series A and Series A-1 convertible preferred stock dividends

-

-

-

-

209

4,130

-

-

Exchange of convertible preferred stock

-

-

-

-

-

3,000

-

-

Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock

-

-

-

-

-

-

2,000

0

Right of use asset obtained in exchange for operating lease liability

620

0

-

-

-

-

-

0

Purchase of property and equipment through short-term financing lease included in accrued expenses and other current liabilities

33

0

-

-

-

-

-

-

Value of Parent Company restricted stock units and common stock issued in lieu of bonuses included in accrued expenses

-

-

-

-

-

-

-

0

Value of Parent Company restricted stock units issued in lieu of cash bonuses

-

-

-

-

-

-

-

0

Fair value of Parent Company stock options modified

-

-

-

-

-

-

-

0

Reclassification of derivative liability upon elimination of obligation

-

-

-

-

-

-

-

0

Fair value of Series A convertible preferred stock beneficial conversion feature

-

-

-

-

-

-

-

9,500

Accretion of Series A convertible preferred stock

-

-

-

-

-

-

-

-9,500

Conversion of notes payable into Series A convertible preferred stock

-

-

-

-

-

-

-

1,000

Conversions of convertible preferred stock into common stock

-

-

-

-

-

3,882

434

224

Cancellation of notes receivable

-

-

150

-

-

-

-

-

Accounts payable assumed

-

-

5

-

-

-

-

-

Fair value of securities issued

-

-

2,824

-

-

-

-

0

Fair value of Parent Company shares mandatorily redeemable for cash upon exercise of warrants

-

-

-

-

-

-

-

0

Allocation of management expenses

-

-

-

-

-

-

-

0

Equipment and furnishings exchanged for Parent Company common stock

-

-

-

-

-

-

-

0

Fair value of securities issued

-

-

-

-

-

-

-

0

Fair value of Series A and Series A-1 convertible preferred stock dividends

-

-

-

-

-

-

8,610

3,315

Series A and Series A-1 convertible preferred stock dividends

-

-

-

-

-

-

682

-

Series B Preferred Stock [Member]
Conversions of convertible preferred stock into common stock

-

-

3,525

-

-

-

-

-

Series C Preferred Stock [Member]
Conversions of convertible preferred stock into common stock

-

-

816

-

-

-

-

-